UK Health Committee Probes Impact Of No-Deal Brexit On Medicines Supply
The BioIndustry Association is planning to contribute to a UK parliamentary inquiry into the likely effects of a “no-deal” Brexit on healthcare and medicines supply, and has urged companies to notify the government of the state of their contingency plans.
You may also be interested in...
Mike Thompson, head of the Association of the British Pharmaceutical Industry, outlined his industry’s concerns over medicines stockpiling, batch testing, tariffs, regulatory collaboration and other issues at a parliamentary committee hearing on the implications of a no-deal Brexit.
The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.
The UK government has published its response to the concerns raised by a parliamentary health committee about the impact of Brexit on medicines and medical devices. However, the response is lacking in detail, and the biotech industry says it does not provide the information companies need to be able to plan for the future.